Source-linked dosage record
WEGOVY dose chart
The Novo Nordisk prescribing record for WEGOVY (semaglutide), organized into a scan-friendly schedule without detaching it from the source document.
- Ingredient
- semaglutide
- Schedule format
- Table published in the label
- Label published
- Jun 30, 2026
- Mirrored
- 2026-08-29
Answer first
Dose schedule
The rows below are reproduced from 2.2 Recommended Dosage for WEGOVY Injection.
Recommended Dosage for WEGOVY Injection
| Weeks | Once-weekly Subcutaneous Injection Dosage | |
|---|---|---|
| Starting Dosage | 1 through 4 | 0.25 mg |
| Dosage Escalation | 5 through 8 | 0.5 mg |
| 9 through 12 | 1 mg | |
| 13 through 16 | 1.7 mg | |
| Maintenance Dosage | 17 and onward | See the indication below for the recommended maintenance dosage(s) |
Rows reproduced from 2.2 Recommended Dosage for WEGOVY Injection; wording retained as published in the captured label.
Recommended Dosage of WEGOVY Tablets
| Days | Once Daily Tablet Dosage | |
|---|---|---|
| Starting Dosage | 1 through 30 | 1.5 mg |
| Dosage Escalation | 31 through 60 | 4 mg |
| 61 through 90 | 9 mg | |
| Maintenance Dosage | 91 and onward | 25 mg |
Rows reproduced from 2.3 Recommended Dosage of WEGOVY Tablets; wording retained as published in the captured label.
The tables above are reproduced from 2.2 Recommended Dosage for WEGOVY Injection and 2.3 Recommended Dosage of WEGOVY Tablets of the WEGOVY prescribing information identified in the source block. CareCanon did not author them, did not reorder any row and did not add a dose.
Section 3 inventory
Strengths and presentations
This inventory is kept separate from the schedule: a marketed strength is not automatically a starting dose, maintenance dose or recommendation.
Marketed strengths in this brand record
- 0.25 mg
- 0.5 mg
- 1 mg
- 1.5 mg
- 1.7 mg
- 2.4 mg
- 4 mg
- 7.2 mg
- 9 mg
- 25 mg
Dosage forms
Injection · Tablet
Named packages
- Single-dose pen
- Single-dose prefilled syringe
- FlexTouch pen · 4 doses
- Tablet
Source excerpt · 3 DOSAGE FORMS AND STRENGTHS
Injection: clear, colorless solution available as follows: Single-Dose Pens Dose per Injection Total Strength per Total Volume 0.25 mg 0.25 mg/0.5 mL 0.5 mg 0.5 mg/0.5 mL 1 mg 1 mg/0.5 mL 1.7 mg 1.7 mg/0.75 mL 2.4 mg 2.4 mg/0.75 mL 7.2 mg (WEGOVY HD) 7.2 mg/0.75 mL Single-Patient-Use Pen (4 doses per Pen) (WEGOVY FlexTouch) Dose per Injection Total Strength per Total Volume 2.4 mg 9.6 mg/3 mL (3.2 mg/mL) Single-Dose Syringes Dose per Injection Total Strength per Total Volume 0.25 mg 0.25 mg/0.5 mL 0.5 mg 0.5 mg/0.5 mL 1 mg 1 mg/0.5 mL 1.7 mg 1.7 mg/0.75 mL 2.4 mg 2.4 mg/0.75 mL Tablets: available as: Tablet Strength Description 1.5 mg White to light yellow, round shaped debossed with “1.5” on one side and “novo” on the other side 4 mg White to light yellow, round shaped debossed with “4” o…
Inspect the complete section on DailyMed ↗Source excerpts
What the label says
These excerpts preserve the section names used by the source. Open DailyMed for the complete prescribing information.
2 DOSAGE AND ADMINISTRATION
In patients with diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. ( 2.1 ) WEGOVY Injection • Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. ( 2.1 ) • Inject subcutaneously in the abdomen, thigh, or upper arm. ( 2.1 ) • Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage. ( 2.2 ) • The usual recommended maintenance dosage of WEGOVY injection is …
2.1 Important Monitoring and Administration Instructions
In patients with diabetes mellitus, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment [see Warnings and Precautions (5.4 )] . Administer WEGOVY in combination with a reduced-calorie diet and increased physical activity. WEGOVY Injection • Inform patients and their caregiver(s) which WEGOVY presentation (e.g., single-dose pen or syringe, or WEGOVY FlexTouch single-patient-use pen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed WEGOVY presentation changes, ensure patients and caregivers receive appropriate…
2.2 Recommended Dosage for WEGOVY Injection
Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications • The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly. • Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] . • If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. Table 1. Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adult…
2.3 Recommended Dosage of WEGOVY Tablets
Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults • The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily. Follow the dosage escalation in Table 2 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] . • If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation. • The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily. • If patients do not tolerate the 25 mg once daily maintenance d…
Document history
Recent label changes
Only changes named in the label’s own recent-major-changes block appear here.
| Section | Change | Revised |
|---|---|---|
| 1 | Indications and Usage | 08/2025 |
| 2 | Dosage and Administration | 08/2025 |
| 5.5 | Warnings and Precautions, Acute Kidney Injury due to Volume Depletion | 08/2025 |
| 5.6 | Severe Gastrointestinal Adverse Reactions | 10/2025 |
| 5.11 | Never Share WEGOVY FlexTouch Between Patients | 06/2026 |
Before using this record
Three useful distinctions
Is this a personal dosing recommendation?
No. It is a reference rendering of prescribing information. A licensed prescriber and pharmacist determine what applies to an individual.
Did the manufacturer publish this exact table?
Yes. The displayed schedule is reproduced from 2.2 Recommended Dosage for WEGOVY Injection.
How can I tell whether the source changed?
Use the publication and mirror dates above, inspect the recent-change rows, and open the linked DailyMed record for the current complete document.